Clinical Trials Browser

INDUSTRY × Multiple Myeloma × 30 days × Clear all

NCT07095452 2026-03-19

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

Multiple Myeloma

NCT07258511 2026-03-19

TRIlogy-4

Phase 3 Recruiting

Multiple Myeloma

NCT05083169 2026-03-18

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Multiple Myeloma

NCT06153251 2026-03-18

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT06980480 2026-03-18

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT04133636 2026-03-17

CARTITUDE-2

Phase 2 Active not recruiting

Multiple Myeloma

NCT04634552 2026-03-17

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT05201781 2026-03-17

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Phase 4 Recruiting

Multiple Myeloma

NCT05552976 2026-03-17

SUCCESSOR-2

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT06068400 2026-03-17

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase NA Terminated

Multiple Myeloma, Recurrence

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07477587 2026-03-17

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma

NCT04181827 2026-03-16

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT05438043 2026-03-16

A Study of Daratumumab

Phase 3 Recruiting

Multiple Myeloma

NCT06934044 2026-03-16

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT07393282 2026-03-16

LINKER-SMM2

Phase 3 Not yet recruiting

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03901963 2026-03-13

AURIGA

Phase 3 Active not recruiting

200 enrolled 12 charts

Multiple Myeloma

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT04923893 2026-03-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT04960579 2026-03-13

MM

Phase 1 Recruiting

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT05652335 2026-03-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1 Recruiting

Amyloidosis, Multiple Myeloma, Recurrence

NCT05827016 2026-03-13

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT05862012 2026-03-13

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Phase 1 Recruiting

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

Phase 3 Recruiting

Multiple Myeloma

NCT06425991 2026-03-13

MajesTEC-10

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT06577025 2026-03-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT06604715 2026-03-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06768489 2026-03-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT07030517 2026-03-13

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

Phase 4 Recruiting

Multiple Myeloma

NCT07149857 2026-03-13

CARTITUDE-10

Phase 2 Recruiting

Multiple Myeloma

NCT07266441 2026-03-13

TRIlogy-3

Phase 2 Recruiting

Multiple Myeloma

NCT05160584 2026-03-12

MoMMent

Multiple Myeloma

NCT05332054 2026-03-12

LTFS

Enrolling by invitation

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT05552222 2026-03-12

MajesTEC-7

Phase 3 Recruiting

Multiple Myeloma

NCT06285318 2026-03-12

REALiTEC/TAL

Multiple Myeloma

NCT07284758 2026-03-12

MOMENTUM

Phase 2 Recruiting

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

Phase 3 Recruiting

Multiple Myeloma

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT06223516 2026-03-11

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03844048 2026-03-06

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05583617 2026-03-06

PLYCOM

Phase 1/2 Recruiting

Multiple Myeloma

NCT06375044 2026-03-06

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07454187 2026-03-06

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07455851 2026-03-06

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT05927571 2026-03-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06045806 2026-03-05

KarMMa-9

Phase 3 Active not recruiting

Multiple Myeloma